Cacna1S Gene Calcium Voltage Gated Channel Alpha Subunit 1S is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| CACNA1S |
|---|
| Full Name | Calcium Voltage-Gated Channel Alpha Subunit 1S |
| Category | Gene |
| Path | /genes/cacna1s |
| Chromosome | 1q31.3 |
| Protein | L-type calcium channel alpha-1S subunit (CaV1.1) |
| Aliases | CaV1.1, CACNL1A3, HPNS1 |
CACNA1S (Calcium Voltage-Gated Channel Alpha Subunit 1S) encodes the alpha-1S subunit of L-type voltage-gated calcium channels, also known as CaV1.1. This gene is located on chromosome 1q31.3 and is primarily expressed in skeletal muscle. CaV1.1 was the first voltage-gated calcium channel to be characterized and is best known for its essential role in excitation-contraction (EC) coupling.
CACNA1S/CaV1.1 has several critical functions:
CaV1.1 serves as the voltage sensor for skeletal muscle EC coupling:
- Upon depolarization, CaV1.1 undergoes conformational changes
- These changes are directly transmitted to ryanodine receptors (RYR1) on the sarcoplasmic reticulum
- This mechanical coupling triggers calcium release without requiring calcium influx (orthograde EC coupling)
While not its primary function in skeletal muscle:
- CaV1.1 can mediate L-type calcium influx when expressed in other tissues
- In some cell types, contributes to calcium-dependent gene transcription
CaV1.1 is a multimeric complex:
- Alpha-1S subunit: The pore-forming subunit (encoded by CACNA1S)
- Alpha-2 delta subunit: Auxiliary subunit enhancing surface expression
- Beta subunit: Auxiliary subunit regulating gating
- Gamma subunit: Auxiliary subunit with modulatory function
CACNA1S mutations cause several neuromuscular disorders:
- Type 1 (HypoPP1): Most commonly caused by CACNA1S mutations
- Pathogenic mechanism: Mutations cause gain-of-function, leading to abnormal sustained sodium channel inactivation
- Clinical features: Episodic weakness, low serum potassium
- CACNA1S mutations are a recognized cause of MH susceptibility
- Triggered by volatile anesthetics and succinylcholine
- Can lead to life-threatening hyperthermia and rhabdomyolysis
- Thyrotoxic periodic paralysis: Interaction between CACNA1S and thyroid hormone
- Congenital myopathies: Some CACNA1S mutations cause static myopathy
CACNA1S shows highly restricted expression:
- Skeletal muscle: Highest expression in fast-twitch (type II) fibers
- Heart: Minimal expression (CaV1.2/CACNA1C is the primary cardiac L-type channel)
- Brain: Very low expression in specific neuronal populations
- Other tissues: Minor expression in some endocrine tissues
CaV1.1 exhibits unique biophysical characteristics:
- Activation threshold: Relatively positive (~ -20 mV)
- Conductance: High single-channel conductance
- Gating: Slow activation and inactivation kinetics
- Pharmacology: Blocked by dihydropyridines (nifedipine, amlodipine), phenylalkylamines (verapamil), and benzothiazepines (diltiazem)
CaV1.1 is a drug target:
- L-type calcium channel blockers (primarily targeting CaV1.2) are used for hypertension and angina
- Muscle-specific calcium channel modulators for periodic paralysis
- Gene therapy approaches for CACNA1S-related myopathies
- CACNA1S in hypokalemic periodic paralysis (2020)
- Structure of CaV1.1 in complex with beta and alpha2-delta (2020)
- Excitation-contraction coupling mechanism (2019)
The study of Cacna1S Gene Calcium Voltage Gated Channel Alpha Subunit 1S has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.